Overview Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Status: Completed Trial end date: 2011-01-01 Target enrollment: Participant gender: Summary This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL). Phase: Phase 3 Details Lead Sponsor: PfizerTreatments: EverolimusSirolimus